Head to Head Analysis: Acusphere (OTCMKTS:ACUS) and Metagenomi (NASDAQ:MGX)

Acusphere (OTCMKTS:ACUS) and Metagenomi (NASDAQ:MGX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, dividends, profitability and risk.

Profitability

This table compares Acusphere and Metagenomi’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Acusphere	N/A	N/A	N/A
Metagenomi	-287.06%	-43.19%	-31.06%

Earnings and Valuation

This table compares Acusphere and Metagenomi”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acusphere	N/A	N/A	N/A	N/A	N/A
Metagenomi	$30.91 million	1.87	-$78.06 million	($2.40)	-0.64

Acusphere has higher earnings, but lower revenue than Metagenomi.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Acusphere and Metagenomi, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acusphere	0	0	0	0	0.00
Metagenomi	1	0	3	1	2.80

Metagenomi has a consensus price target of $10.00, indicating a potential upside of 549.35%. Given Metagenomi’s stronger consensus rating and higher probable upside, analysts clearly believe Metagenomi is more favorable than Acusphere.

Risk & Volatility

Acusphere has a beta of -2.22, indicating that its stock price is 322% less volatile than the S&P 500. Comparatively, Metagenomi has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500.

Summary

Metagenomi beats Acusphere on 6 of the 9 factors compared between the two stocks.

About Acusphere

Acusphere, Inc. operates as a specialty pharmaceutical company that develops and commercializes cardiovascular drugs. It offers Imagify (perflubutane polymer microspheres), a cardiovascular drug that evaluates myocardial perfusion and detects coronary artery disease. It provides Imagify as an injectable suspension. The company was formerly known as Polymers For Medicine, Inc. and changed its name to Acusphere, Inc. in March 2004. Acusphere, Inc. was founded in 1993 and is based in Watertown, Massachusetts.

About Metagenomi

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.